Aim: To evaluate the impact of antiplatelet therapy (APT)on the incidence of hepatocellular carcinoma (HCC) and mortality following its treatment. Methods: A systematic literature search was performed using PubMed and Cochrane Central Register of Controlled Trials Databases. Two HCC clinical settings were explored: (i) incidence, and (ii) death after any HCC treatment. Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the pooled data between patients who received or did not receive APT. Results: A total of 20 studies were identified, of whom 15 focused on HCC incidence, including 2,685,009 patients, and five on post-treatment death, including 3281 patients. APT was associated with an overall reduced risk of HCC incidence (OR: 0.63; 95%CI = 0.51–0.79; p < 0.001) as well as of post-treatment mortality (OR: 0.54; 95%CI = 0.35–0.83; p = 0.006). Conclusions: Current data suggest that APT correlated with higher HCC incidence and poor overall survival following tumour treatment.
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma / Lai, Q.; De Matthaeis, N.; Finotti, M.; Galati, G.; Marrone, G.; Melandro, F.; Morisco, F.; Nicolini, D.; Pravisani, R.; Giannini, E. G.; Aglitti, A.; Aliberti, C.; Baccarani, U.; Bhoori, S.; Borzio, M.; Brancaccio, G.; Burra, P.; Cabibbo, G.; Casadei Gardini, A.; Carrai, P.; Cillo, U.; Conti, F.; Cucchetti, A.; D'Ambrosio, R.; Dell'Unto, C.; Di Costanzo, G. G.; Di Sandro, S.; Foschi, F. G.; Fucilli, F.; Gambato, M.; Gasbarrini, A.; Giuliante, F.; Ghinolfi, D.; Grieco, A.; Gruttaduria, S.; Guarino, M.; Kostandini, A.; Iavarone, M.; Lenci, I.; Levi Sandri, G. B.; Losito, F.; Lupo, L. G.; Manzia, T. M.; Mazzocato, S.; Mescoli, C.; Miele, L.; Muley, M.; Persico, M.; Plaz Torres, M. C.; Pompili, M.; Ponziani, F. R.; Rapaccini, G. L.; Rendina, M.; Renzulli, M.; Rossi, M.; Rreka, E.; Russo, F. P.; Sacco, R.; Sangiovanni, A.; Sessa, A.; Simonetti, N.; Sposito, C.; Tortora, R.; Trevisani, F.; Vigano, L.; Vigano, M.; Villa, E.; Vincenzi, V.; Violi, P.; Vitale, A.. - In: THE EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. - ISSN 0014-2972. - 53:1(2023). [10.1111/eci.13870]
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma
Casadei Gardini A.;Conti F.;D'Ambrosio R.;Trevisani F.;
2023-01-01
Abstract
Aim: To evaluate the impact of antiplatelet therapy (APT)on the incidence of hepatocellular carcinoma (HCC) and mortality following its treatment. Methods: A systematic literature search was performed using PubMed and Cochrane Central Register of Controlled Trials Databases. Two HCC clinical settings were explored: (i) incidence, and (ii) death after any HCC treatment. Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the pooled data between patients who received or did not receive APT. Results: A total of 20 studies were identified, of whom 15 focused on HCC incidence, including 2,685,009 patients, and five on post-treatment death, including 3281 patients. APT was associated with an overall reduced risk of HCC incidence (OR: 0.63; 95%CI = 0.51–0.79; p < 0.001) as well as of post-treatment mortality (OR: 0.54; 95%CI = 0.35–0.83; p = 0.006). Conclusions: Current data suggest that APT correlated with higher HCC incidence and poor overall survival following tumour treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
